|国家科技期刊平台
首页|期刊导航|中国药理学通报|前动力蛋白受体2在心脑血管及神经退行性疾病治疗中的研究进展

前动力蛋白受体2在心脑血管及神经退行性疾病治疗中的研究进展OA北大核心CSTPCD

Research progress of PK2 in treatment of cardio-cerebrovascular and neurodegenerative diseases

中文摘要英文摘要

心脑血管及神经退行性疾病是好发于中老年人群的常见疾病,具有较高的致残率和病死率,严重威胁着人类健康.前动力蛋白受体2(prokineticin 2,PK2)是新发现的一种分泌性蛋白,通过与其受体(prokineticin receptor,PKR)1或2结合,在许多生理病理过程中发挥着重要的作用.与PK2/PKRs相关的众多研究显示,该信号通路在心脑血管及神经退行性疾病的发生发展过程中扮演着十分重要的角色,通过研究探讨它们之间的联系,PK2/PKRs将可能成为临床上治疗该类疾病的新靶点.

Cardio-cerebrovascular and neurodegenerative diseases are diseases of high-incidence diseases among middle-aged and elderly people,with high disability and mortality rates,which se-riously threaten human health.PK2 is a newly discovered secre-ted protein that plays an important role in many physiological and pathological processes by binding to its receptor PKR1 or 2.Numerous studies related to PK2/PKRs have shown that this sig-naling pathway also plays a very important role in the occurrence and development of cardiovascular,cerebrovascular and neuro-degenerative diseases,and through exploring the connection be-tween them,PK2/PKRs may become a new target for the clini-cal treatment of these diseases.

李峰;付建华;张路;姚明江

中国中医科学院西苑医院基础医学研究所,中药药理北京市重点实验室中国中医科学院西苑医院针灸科,北京 100091

基础医学

前动力蛋白受体心血管疾病脑血管疾病神经退行性疾病作用机制

PK2cardiovascular diseasescerebrovascular dis-easesneurodegenerative diseasesmechanism of action

《中国药理学通报》 2024 (008)

1401-1407 / 7

中国中医科学院科技创新工程重大攻关项目(No C12021A01305,C12021A00912);国家中医药管理局中医药创新团队及人才支持计划项目(No ZYYCXTD-C-202007)

10.12360/CPB202301061

评论